Back to Agenda
Session 6: EU Updates
Session Chair(s)
Michael Richardson, MD, FFPM, FRCP
Senior Vice President, WorldWide Patient Safety
Bristol-Myers Squibb, United Kingdom
Requirements and expectations for pharmacovigilance in the EEA continue to evolve with the objective of improving patient safety. This session will explore recent developments related to pharmacovigilance. The focus will be on the evolving situation in the EEA, set in a global context. In addition, this session will include strategic updates on Module VI and E2D (ICH) and data from PSPs; an update on “Brexit” an industry perspective from an EU perspective and a regulator perspective from the MHRA. Additionally an overview of Rev 2 of Module V (RMP) and removal of risks from RMPs.
Learning Objective :
At the conclusion of this session, participants should be able to:- Describe key new pharmacovigilance requirements in the EEA
- Understand the implications of the various Brexit scenarios
- Outline plans and contingencies for UK/EU organizational changes and Pharmacovigilance operations in the UK
Speaker(s)
Exiting the EU – The Impact on EU Pharmacovigilance Activities
Mick Foy
Medicines and Healthcare Products Regulatory Agency (MHRA), United Kingdom
Director of Delivery
BREXIT: Impact on Pharmacovigilance
Vicki Edwards, RPh
Abbvie, United Kingdom
Vice President, Pharmacovigilance Excellence and International QPPV
EU Risk Management Planning GVP V (Rev2)
Valerie E. Simmons, MD, FFPM
Eli Lilly and Company Ltd, United Kingdom
Senior Medical Fellow, Global Patient Safety
Have an account?